Pharmaceutical Manufacturing Execution System Companies

The pharmaceutical MES market is projected to reach USD 4.62 billion by 2030 from USD 2.37 billion in 2025, at a CAGR of 14.3% from 2025 to 2030. Growth of MES in the pharmaceutical and broader life sciences sector is driven by increasing regulatory requirements for GMP compliance, data integrity, and electronic batch records, making manufacturing execution systems essential. The rise of biologics, cell and gene therapies, and personalized medicines demands highly flexible, traceable, and automated manufacturing processes that MES enables. Additionally, the adoption of Industry 4.0, the integration of AI/analytics for real-time quality control, and the need to minimize production errors and downtime further fuel demand for MES. The growing focus on operational efficiency, standardization across multi-site facilities, and faster time-to-market also accelerates the deployment of MES in the life sciences.

Competition in the pharmaceutical MES market is intense and fragmented. Vendors differentiate themselves through validated, pharma-specific modules, cloud versus on-premises models, and services. Major players in the pharmaceutical manufacturing execution system market include Siemens (Germany), Yokogawa Electric (Japan), Schneider Electric (France), and niche life-sciences vendors such as Werum/Körber (Germany) and Aptean (Georgia), among others. Product launches, collaborations, and acquisitions are key strategies adopted by players to increase their market share, enhance their product portfolios, and expand their presence in the pharmaceutical manufacturing execution system market.

To know about the assumptions considered for the study download the pdf brochure

In December 2025, Rockwell Automation announced a series of strategic innovations to its Manufacturing Execution System (MES) portfolio, focused on flexibility, scalability, and resiliency. This elastic MES portfolio is a cloud-native, interoperable MES platform designed to unify manufacturing operations across various industries, including pharmaceutical, food & beverage, and other sectors.

In September 2025, Körber announced the release of the new PAS-X MES 3.4, a robust upgrade to its Manufacturing Execution System that will facilitate the digital transformation of pharmaceutical manufacturing as well as life science applications. It offers modern UI/UX, AI-based user support, and intelligent lifecycle management, all designed to facilitate faster, more flexible shop-floor operations and ensure regulatory compliance.

The key players operating in the Europe Manufacturing Execution System market include Siemens (Germany), Dassault Systèmes (France), SAP SE (Germany), ABB (Switzerland), Rockwell Automation (US), Honeywell International Inc. (US), Yokogawa Electric (Japan), Schneider Electric (France), Emerson Electric Co. (US), among others.

Siemens (Germany)

Siemens, formerly known as Siemens & Halske, is a German electrical and electronics engineering company focusing on electrification, automation, and digitalization. The company offers products, services, and solutions for effectively using resources and energy. It operates through the following business segments: Digital Industries, Smart Infrastructure, Mobility, Siemens Healthineers, and Siemens Financial Services. Siemens’ manufacturing execution systems (MES), quality management systems (QMS), advanced planning and scheduling (APS), and enterprise manufacturing intelligence (EMI) solutions are a part of its manufacturing operations management (MOM) systems. These solutions provide a comprehensive approach to enhancing the performance of manufacturing operations and consolidating the management of production execution, sequencing, nonconformance handling, and end-to-end quality within a single system.

SAP SE (Germany)

SAP SE provides enterprise application software and software-related services. The company’s core focus lies in developing and providing integrated enterprise resource planning (ERP) software, customer relationship management (CRM) solutions, supply chain management (SCM) tools, and various other business applications. Its offerings are designed to streamline and optimize business operations, enhance productivity, and foster innovation across multiple business functions. It operates in two business segments: Cloud & Software and Services. The Cloud & Software segment is further sub-segmented into Cloud, Software Licenses, and Software Support.

Market Ranking

The pharmaceutical manufacturing execution system market is competitive, with five main players collectively accounting for a significant market share. Siemens holds a significant market share in the pharmaceutical manufacturing execution system market due to its robust software portfolio. Similarly, SAP SE maintains a leading share in the pharmaceutical MES market, driven by strong demand for its manufacturing execution systems. Its brand reputation, regional manufacturing footprint, and alignment with smart manufacturing initiatives, as well as large-scale modernization of legacy production facilities and the growing need for real-time visibility, strengthen its influence across key regions in the pharmaceutical MES market.

Related Reports:

Pharmaceutical Manufacturing Execution System (MES) Market By Offering (Software, Services), Deployment (On-premises, Cloud, Hybrid), Application (Production Management, Quality Management, Performance Analytics, Predictive Maintenance) - Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com